These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7509536)

  • 1. Endocrine therapies for symptomatic benign prostatic hyperplasia.
    Oesterling JE
    Urology; 1994 Feb; 43(2 Suppl):7-16. PubMed ID: 7509536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.
    Oesterling JE; el Etreby MF; Gormley GJ; Imperato-McGinley JL; Roehrborn CG; Schröder FH; Tunn UW
    Prog Clin Biol Res; 1994; 386():231-50. PubMed ID: 7528391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of benign prostatic hypertrophy.
    Geller J
    Urology; 1989 Oct; 34(4 Suppl):57-63; discussion 87-96. PubMed ID: 2477935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy for benign prostatic hyperplasia.
    Keetch DW; Andriole GL
    AJR Am J Roentgenol; 1995 Jan; 164(1):11-5; discussion 16-7. PubMed ID: 7527995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drug therapies for benign prostatic hyperplasia.
    Bullock TL; Andriole GL
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):111-23. PubMed ID: 16503830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drugs for the treatment of benign prostatic hypertrophy].
    Caprino L
    Minerva Urol Nefrol; 2000 Jun; 52(2):87-92. PubMed ID: 11085067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
    Ekman P
    Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
    Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P
    Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal manipulation of benign prostatic hyperplasia.
    Rick FG; Saadat SH; Szalontay L; Block NL; Kazzazi A; Djavan B; Schally AV
    Curr Opin Urol; 2013 Jan; 23(1):17-24. PubMed ID: 23202285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of prostatic diseases.
    Schlegel PN
    Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R
    Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
    J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists.
    Monda JM; Oesterling JE
    Mayo Clin Proc; 1993 Jul; 68(7):670-9. PubMed ID: 7688840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benign prostatic hyperplasia: an insight into current investigational medical therapies.
    Tiwari A; Krishna NS; Nanda K; Chugh A
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1359-72. PubMed ID: 16255676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing approaches in the treatment of benign prostatic hyperplasia.
    Schröder FH
    Eur Urol; 1991; 20 Suppl 1():63-7. PubMed ID: 1722165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.
    Peters DH; Sorkin EM
    Drugs; 1993 Jul; 46(1):177-208. PubMed ID: 7691505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
    Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.